Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Boehringer Ingelheim opens new green energy power plant

By Sean Whooley | July 8, 2024

Boehringer Ingelheim green power carbon neutral plant

The Ingelheim biomass plant. [Image courtesy of Boehringer Ingelheim]

Boehringer Ingelheim announced today that it inaugurated a biomass powerplant at its Ingelheim, Germany site.

The pharmaceutical company — one of the largest in the world — opened the new plant to optimize its energy supply and protect the environment. With the new plant, the company expects to save around 50,000 tons of CO2. It says the plant reduces the CO2 emissions of the site’s own energy generation by 70%.

In total, Boehringer Ingelheim plans to invest €205 million (nearly $222 million) in sustainable infrastructure projects at the Ingelheim site. It expects to cover 95% of its energy requirements from renewable sources in the future. The company set a goal of making its business operations CO2-neutral by 2030. Its sites in Dortmund, Germany, Gainesville, Georgia (U.S.), Zhangjian, China, and Sant Cugat, Spain, all have carbon-neutral certification.

German Vice Chancellor and Federal Minister of Economics Robert Habeck and Rhineland-Palatinate Environment Minister Katrin Eder attended the company’s ceremonial inauguration for the green energy plant.

“Part of our sustainability goals is to protect natural resources so that our earth remains a place worth living in for people and animals. With an environmentally friendly and more independent energy supply, we are ensuring stable production in order to be able to deliver medications for patients worldwide,” said Michael Schmelmer, vice chair of the Boehringer Ingelheim board.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE